Matt Hoffman

Branded as Nexviazyme, Sanofi’s enzyme replacement therapy demonstrated key improvements in measures of disease burden while maintaining its known safety profile.

Cummings and colleagues presented appropriate use criteria for the newly approved Biogen/Eisai agent at the 2021 Alzheimer’s Association International Conference.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jessica Zwerling, MD, MS.

Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).

Pooled data from the phase 3 clinical development of aducanumab (Aduhelm; Biogen) suggest that ARIA remains a mostly asymptomatic problem, with MRI providing an effective way to monitor events.

Alfred Sandrock, MD, PhD, head of research and development, Biogen, has published an open letter to the Alzheimer community in an attempt to clarify “misinformation and misunderstanding” that has moved “outside the boundaries of legitimate scientific deliberation.”

Raman Malhotra, MD, associate professor of neurology, Washington University in St. Louis, and president, AASM, discussed the state of research in sleep medicine and the gaps in care that need to be addressed.

The development of agents for MS to address the treatment needs of patients with progressive and relapsing disease has been an ongoing effort that has brought forth a few new potential disease-modifying therapies.

Raman Malhotra, MD, associate professor of neurology, Washington University in St. Louis, and president, AASM, discussed the initiative to increase awareness of healthy sleep.

Jessica Zwerling, MD, associate director, Center for the Aging Brain, Montefiore Medical Center, discussed the impact that telemedicine has had in Alzheimer and dementia care.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Raman Malhotra, MD.

The data suggest that women considered at high relapse risk or with poor prognostic factors benefit peripregnancy from high-efficacy therapy continuation.

Lucie Barateau, MD, assistant professor of neurology, Hôpital Gui De Chauliac, offered insight on the usefulness of the newly developed pediatric narcolepsy type 1 severity scale.

Janet Woodcock, MD, acting commissioner of the FDA, called for an inquiry by the Office of the Inspector General into possible interactions between agency officials and Biogen that "may have occurred outside of the formal correspondence process."

The original Narcolepsy Severity Scale was reformulated with the driving-related item removed to assess a pediatric version for the school-aged and adolescent narcolepsy type 1 population.

Maromi Nei, MD, and Michael R. Sperling, MD, shared their insight on the novel inventory tool for predicting sudden unexpected death in epilepsy and their recently published work.

ICER’s health-benefit price benchmark range for aducanumab is $3000 to $8400 per year for patients with early Alzheimer disease, substantially lower than the current $56,000 annual price listing.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Scott D. Newsome, DO, and David Li, MD, FRCPC.

The SUDEP-3 outperformed the prior SUDEP-7 variation on all measures, and simplifies the risk assessment with a 3-item weighted scoring while enhancing the clinical practicality.

Robert Zivadinov, MD, PhD, director, Buffalo Neuroimaging Analysis Center, spoke to the findings of a post-hoc analysis of atrophied T2-lesion volume as a biomarker in patients with progressive MS.

Data presented at SLEEP 2021 from Study 303 suggest that long-term use of lemborexant is well received by patients, who reported that the agent helped them fall asleep and improved total sleep time.

Deena Kuruvilla, MD, the medical director of the Westport Headache Institute spoke to the potential of e-TNS in the treatment of migraine overall and which gaps in care that it might fill.

The calcium, magnesium, potassium, and sodium oxybates oral solution, marketed as Xywav, is currently also under review for the treatment of idiopathic hypersomnia, with an FDA decision expected by August 12, 2021.

The CEO of CENTOGENE discussed the recently announced EFRONT study in FTD and the role that rare disease genetic data collection can play in providing insights into disease intervention and treatment.

The Idorsia dual orexin receptor antagonist was accepted by the FDA for review in March 2021 and has shown efficacy in a number of SLEEP 2021 poster presentations.

Luca Giliberto, MD, PhD, and Cristina d’Abramo, PhD, share more than a marriage: After years of research, their combined efforts to develop a passive immunotherapy for Alzheimer disease have earned them a $2 million grant from the National Institutes of Health.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Michael J. Thorpy, MD.

Biogen’s investigational antibody against the N-terminus of tau failed to meet any of the efficacy or exploratory end points in individuals with mild cognitive impairment or mild Alzheimer disease.

Two experts in pediatric MS care, Lauren B. Krupp, MD, and Tanuja Chitnis, MD, offer tips and insight on the diagnosis of the disease and the specific challenges faced by patients stemming from their own clinical experience.

Here's what is coming soon to NeurologyLive.